Cardiol Therapeutics Inc.
CRDL.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.53M
Close$
Share Statistics
| Market cap | $162.53 Million |
|---|---|
| Enterprise Value | $136.55 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -152.53% |
|---|---|
| Return on Assets | -124.84% |
| Return on Invested Capital | -152.07% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.73 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cardiol Therapeutics Inc
18 employees
CEO: David G. Elsley Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. It...